↧
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth starts bluebird bio at buy
Roth Capital Partners has launched coverage of bluebird bio (NASDAQ:BLUE) with a “buy” rating and $50 price target. The stock closed at $36.63 on Friday. “With its proprietary Lentiviral vectors, the...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Kadimastem plans stem cell therapy trial for ALS in late 2016
Dr. Arik Hasson Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for...
View ArticleKadimastem plans stem cell therapy trial for ALS in late 2016
Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for Amyotrophic Lateral...
View Article